Immucell (ICCC) Payables (2010 - 2026)

Immucell (ICCC) has reported Payables for 17 consecutive years, with $2.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 8.48% year-over-year to $2.8 million; the trailing twelve-month figure through Jun 2026 stood at $2.8 million (up 8.48% YoY), and the FY2025 full-year result was $2.3 million, down 8.05% from the prior year.
• Payables climbed to $2.8 million in Q2 2026 per ICCC's latest filing, from $2.3 million in the prior quarter.
• Across five years, Payables topped out at $2.8 million in Q2 2026 and bottomed at $1.5 million in Q1 2022.
• Historically, Payables has averaged $2.1 million across 5 years, with a median of $2.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Payables jumped 43.3% in 2022, then fell 8.13% in 2025.
• Over 5 years, Payables stood at $2.0 million in 2022, then grew by 6.17% to $2.1 million in 2023, then gained by 16.86% to $2.5 million in 2024, then declined by 8.05% to $2.3 million in 2025, then gained by 23.01% to $2.8 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $2.8 million, $2.3 million, and $2.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.